Encompass Health’s (EHC) “Buy” Rating Reaffirmed at Robert W. Baird

Robert W. Baird restated their buy rating on shares of Encompass Health (AMEX:EHC) in a research report sent to investors on Friday morning. The brokerage currently has a $59.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. SunTrust Banks set a $58.00 price target on shares of Encompass Health and gave the company a buy rating in a research report on Thursday, December 21st. Zacks Investment Research raised shares of Encompass Health from a hold rating to a buy rating and set a $52.00 price target on the stock in a research report on Monday, October 30th. Royal Bank of Canada reaffirmed a buy rating on shares of Encompass Health in a research report on Wednesday, November 15th. Mizuho raised shares of Encompass Health from a neutral rating to a buy rating and set a $55.00 target price on the stock in a research report on Thursday, November 2nd. Finally, Piper Jaffray Companies reaffirmed a hold rating and issued a $50.00 target price on shares of Encompass Health in a research report on Sunday, September 17th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $53.11.

Encompass Health (AMEX EHC) traded up $0.95 during trading on Friday, hitting $51.46. 587,652 shares of the stock were exchanged, compared to its average volume of 705,338. Encompass Health has a fifty-two week low of $38.24 and a fifty-two week high of $52.58. The stock has a market capitalization of $4,960.00, a price-to-earnings ratio of 18.78, a price-to-earnings-growth ratio of 1.70 and a beta of 0.54. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.34 and a quick ratio of 1.34.

Encompass Health (AMEX:EHC) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.01. The firm had revenue of $995.60 million for the quarter, compared to analysts’ expectations of $985.75 million. Encompass Health had a net margin of 8.67% and a return on equity of 23.56%. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.65 EPS. equities analysts expect that Encompass Health will post 2.72 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 16th. Stockholders of record on Tuesday, January 2nd will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Friday, December 29th. This represents a $1.00 annualized dividend and a dividend yield of 1.94%. Encompass Health’s dividend payout ratio is presently 36.50%.

In other Encompass Health news, Director Yvonne M. Curl purchased 1,000 shares of Encompass Health stock in a transaction dated Wednesday, November 1st. The shares were acquired at an average price of $45.95 per share, with a total value of $45,950.00. Following the completion of the transaction, the director now owns 64,144 shares of the company’s stock, valued at $2,947,416.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

An institutional investor recently bought a new position in Encompass Health stock. Dalton Greiner Hartman Maher & Co. bought a new position in shares of Encompass Health Corp (AMEX:EHC) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 331,823 shares of the company’s stock, valued at approximately $16,395,000. Dalton Greiner Hartman Maher & Co. owned 0.34% of Encompass Health as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 93.18% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Encompass Health’s (EHC) “Buy” Rating Reaffirmed at Robert W. Baird” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/01/13/encompass-healths-ehc-buy-rating-reaffirmed-at-robert-w-baird.html.

Encompass Health Company Profile

Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.

Analyst Recommendations for Encompass Health (AMEX:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit